Early management of ST elevation myocardial infarction: a review of practice

Bibliography

• MCNAMARA RL, HERRIN J, BRADLEY EH et al.: Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J. Am. Coll. Cardiol. (2006) 47:45-51.
   PubMed Web of Science ®Google Scholar
• ROGERS WJ, CANTO JG, LAMBREW CT et al.: Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J. Am. Coll. Cardiol. (2000) 36:2056-2063.
   PubMed Web of Science ®Google Scholar
• DE LUCA G, SURYAPRANATA H, ZIJLSTRA F et al.: for the ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J. Am. Coll. Cardiol. (2003) 42:991-997.
   PubMedGoogle Scholar
• BOERSMA E, MERCADO N, POLDERMANS D et al.: Acute myocardial infarction. Lancet (2003) 361:847-858.
   PubMed Web of Science ®Google Scholar
• DE LUCA G, SURYAPRANATA H, OTTERVANGER JP et al.: Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation (2004) 109:1223-1225.
   PubMedGoogle Scholar
• WEAVER WD, SIMES RJ, BETRIU A et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 278:2093-2098.
   PubMed Web of Science ®Google Scholar
• ZIJLSTRA F, HOORNTJE JC, DE BOER MJ et al.: Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. (1999) 341:1413-1419.
   PubMed Web of Science ®Google Scholar
• KEELEY EC, BOURA JA, GRINES CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 361:13-20.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, ANBE DT, ARMSTRONG PW et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation (2004) 110:e82-e292.
   PubMed Web of Science ®Google Scholar
• MAGID DJ, CALONGE BN, RUMSFELD JS et al.: Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty versus thrombolytic therapy. JAMA (2000) 284:3131-3138.
   PubMed Web of Science ®Google Scholar
• CANNON CP, GIBSON CM, LAMBREW CT et al.: Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA (2000) 283:2941-2947.
   PubMed Web of Science ®Google Scholar
• BERGER PB, ELLIS SG, HOLMES DR Jr et al.: Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation (1999) 100:14-20.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HR, NIELSEN TT, RASMUSSEN K et al.: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N. Engl. J. Med. (2003) 349:733-742.
   PubMed Web of Science ®Google Scholar
• NALLAMOTHU BK, BATES ER: Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am. J. Cardiol. (2003) 92:824-826.
   PubMed Web of Science ®Google Scholar
• MORROW DA, ANTMAN EM, CHARLESWORTH A et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 102:2031-2037.
   PubMed Web of Science ®Google Scholar
• LEE KL, WOODLIEF LH, TOPOL EJ et al.: for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation (1995) 91:1659-1668.
   PubMed Web of Science ®Google Scholar
• MORROW DA, ANTMAN EM, GIUGLIANO RP et al.: A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 358:1571-1575.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, GOLDBERG RJ, DABBOUS O et al.: for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch. Intern. Med. (2003) 163:2345-2353.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS KF, DABBOUS OH, FLATHER MD et al.: GRACE Investigators. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart (2005) 91:290-298.
   PubMed Web of Science ®Google Scholar
• BOERSMA E, MAAS AC, DECKERS JW et al.: Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet (1996) 348:771-775.
   PubMed Web of Science ®Google Scholar
• WIDIMSKY P, BUDESINSKY T, VORAC D et al.: Long distance transport for primary angioplasty versus immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur. Heart J. (2003) 24:94-104.
   PubMed Web of Science ®Google Scholar
• DANCHIN N, BLANCHARD D, STEG PG et al.: Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation (2004) 110:1909-1915.
   PubMed Web of Science ®Google Scholar
• STEG PG, BONNEFOY E, CHABAUD S et al.: Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation (2003) 108:2851-2856.
   PubMed Web of Science ®Google Scholar
• TAHER T, FU Y, WAGNER GS et al.: Aborted myocardial infarction in patients with ST-segment elevation: insights from the assessment of the safety and efficacy of a new thrombolytic regimen-3 trial electrocardiographic substudy. J. Am. Coll. Cardiol. (2004) 44:38-43.
   PubMed Web of Science ®Google Scholar
• FRANZOSI MG, SANTORO E, DE VITA C et al.: Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 study. The GISSI Investigators. Circulation (1998) 24:2659-2665.
   Google Scholar
• WHITE HD: Thrombolytic therapy in the elderly. Lancet (2000) 356:2028-2030.
   PubMed Web of Science ®Google Scholar
• STENESTRAND U, WALLENTIN L: Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch. Intern. Med. (2003) 163:965-971.
   PubMedGoogle Scholar
• FIBRINOLYTIC THERAPY TRIALISTS (FTT) COLLABORATIVE GROUP: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet (1994) 343:311-322.
   PubMed Web of Science ®Google Scholar
• MORRISON LJ, VERBEEK PR, MCDONALD AC et al.: Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA (2000) 283:2686-2692.
   PubMed Web of Science ®Google Scholar
• PEDLEY DK, BISSETT K, CONNOLLY EM et al.: Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. Br. Med. J. (2003) 327:22-26.
   PubMedGoogle Scholar
• MORROW DA, ANTMAN EM, SAYAH A et al.: Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of the Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J. Am. Coll. Cardiol. (2002) 40:71-77.
   PubMed Web of Science ®Google Scholar
• BONNEFOY E, LAPOSTOLLE F, LEIZOROVICZ A et al.: Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet (2002) 360:825-829.
   PubMed Web of Science ®Google Scholar
• WALLENTIN L, GOLDSTEIN P, ARMSTRONG PW et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 plus randomized trial in acute myocardial infarction. Circulation (2003) 108:135-142.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RJ, STEG PG, SADIQ I et al.: Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am. J. Cardiol. (2002) 89:791-796.
   PubMed Web of Science ®Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation (1997) 95(4):846-854
   PubMed Web of Science ®Google Scholar
• THE PARADIGM INVESTIGATORS: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J. Am. Coll. Cardiol. (1998) 32:2003-2010.
   PubMedGoogle Scholar
• TOPOL EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet (2001) 357:1905-1914.
   PubMed Web of Science ®Google Scholar
• ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605-613.
   PubMed Web of Science ®Google Scholar
• GERSHLICK AH, STEPHENS-LLOYD A, HUGHES S et al.: Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. (2005) 353:2758-2768.
   PubMedGoogle Scholar
• Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. JAMA (1988) 260:2849-2858.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, ARNOLD AE, BETRIU A et al.: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet (1988) 1:197-203.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, MEHILLI J, SCHLOTTERBECK K et al.: Early administration of reteplase plus abciximab versus abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA (2004) 291:947-954.
   PubMed Web of Science ®Google Scholar
• ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW TREATMENT STRATEGY WITH PERCUTANEOUS CORONARY INTERVENTION (ASSENT-4 PCI) INVESTIGATORS: Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet (2006) 367:569-578
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-AVILES F, ALLONSO JJ, CASTRO-BEIRAS A et al.: Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet (2004) 364:1045-1053
   PubMed Web of Science ®Google Scholar
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet (1988) 2:349-360.
   PubMed Web of Science ®Google Scholar
• SABATINE MS, CANNON CP, GIBSON CM et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. (2005) 352:1179-1189.
   PubMed Web of Science ®Google Scholar
• SABATINE MS, CANNON CP, GIBSON CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 294:1224-1232.
   PubMed Web of Science ®Google Scholar
• CHEN Z: Randomized, placebo-controlled trial of adding clopidogrel to aspirin in 46,000 acute myocardial infarction patients. Presented at ACC for the COMMIT/CCS-2 investigators (March 9, 2005).
   Google Scholar
• BAIGENT C, COLLINS R: Aspirin and heparin. In: Clinical Trials in Cardiovascular Disease: Companion to Braunwald’s Heart Disease. In Hennekens CH (Ed.), WB Saunders, PA, USA (1999):60.
   Google Scholar
• Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet (1993) 342:759-766
   PubMed Web of Science ®Google Scholar
• WALLENTIN L, GOLDSTEIN P, ARMSTRONG PW et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation (2003) 108:135-142.
   PubMed Web of Science ®Google Scholar
• SABATINE MS, MORROW DA, MONTALESCOT G et al.: Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation (2005) 112:3846-3854.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, QUINLAN DJ, MEHTA SR et al.: Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction. A meta-analysis of the randomized trials. Circulation (2005) 112:3855-3867.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM MORROW DA MCCABE CH et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. (2006) 354:1477-1488.
   PubMed Web of Science ®Google Scholar
• WHITE H: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet (2001) 358:1855-1863.
   PubMed Web of Science ®Google Scholar
• DIRECT THROMBIN INHIBITOR TRIALISTS' COLLABORATIVE GROUP: Direct Thrombin Inhibitor Trialists’ Collaborative Group: direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients’ data. Lancet (2002) 359:294-302.
   PubMed Web of Science ®Google Scholar
• SALIM YUSUF: Effects of fondaparinux on mortality and re-infarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. Presented at the ACC Late Breaking Clinical Trial on March 14, 2006.
   Google Scholar
• CHEN ZM, PAN HC, CHEN YP et al.: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 366:1622-1632.
   PubMed Web of Science ®Google Scholar
• CHAE CU: Beta blockers. In: Clinical Trials in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Hennekens CH (Ed.), WB Saunders, PA, USA (1999):84.
   Google Scholar
• FREEMANTLE N, CLELAND J, YOUNG P et al.: β-Blockade after myocardial infarction: systematic review and meta regression analysis. Br. Med. J. (1999) 318:1730-1737.
   PubMed Web of Science ®Google Scholar
• DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet (2001) 357:1385-1390.
   PubMed Web of Science ®Google Scholar
• THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821-828.
   PubMed Web of Science ®Google Scholar
• AMBROSIONI E, BORGHI C, MAGNANI B et al.: Effects of the early administration of zofenopril on mortality and morbidity in patients with anterior myocardial infarction: results of the Survival of Myocardial Infarction Long-Term Evaluation Trial. N. Engl. J. Med. (1995) 332:80-85.
   PubMed Web of Science ®Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (1995) 333:1670-1676.
   PubMed Web of Science ®Google Scholar
• ISIS-4 COLLABORATIVE GROUP: ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet (1995) 345:669-685.
   PubMed Web of Science ®Google Scholar
• GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL’INTARTO MIOCARDICO: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet (1994) 343:1115-1122.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, HELD P, KJEKSHUS J et al.: Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. (1992) 327:678-684.
   PubMed Web of Science ®Google Scholar
• ACE INHIBITOR MYOCARDIAL INFARCTION COLLABORATIVE GROUP: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation (1998) 97:2202-2212.
   PubMed Web of Science ®Google Scholar
• RUTHERFORD JD, PFEFFER MA, MOYE LA et al.: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation (1994) 90:1731-1738.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360:752-760.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA: Effects of valsartan relative to captopril in patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction. N. Engl. J. Med. (2003) 349:1893-1906.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
   PubMed Web of Science ®Google Scholar
• PRASAD A, STONE GW, AYMONG E et al.: Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. Am. Heart J. (2004) 147:669-675.
   PubMedGoogle Scholar
• ITO H, TOMOOKA T, SAKAI N et al.: Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation (1992) 85:1699-1705.
   PubMed Web of Science ®Google Scholar
• VERMA S, FEDAK PW, WEISEL RD et al.: Fundamentals of reperfusion injury for the clinical cardiologist. Circulation (2002) 105:2332-2336.
   PubMed Web of Science ®Google Scholar
• LIM SY, BAE EH, JEONG MH et al.: Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ. J. (2004) 68:928-932.
   Google Scholar
• MARZILLI M, ORSINI E, MARRACCINI P et al.: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation (2000) 101:2154-2159.
   PubMed Web of Science ®Google Scholar
• STONE GW, WEBB J, COX DA et al.: Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA (2005) 293:1063-1072.
   PubMed Web of Science ®Google Scholar
• COSTANTINI CO, STONE GW, MEHRAN R et al.: Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J. Am. Coll. Cardiol. (2004) 44:305-312.
   PubMedGoogle Scholar
• ASSMUS B, SCHACHINGER V, TEUPE C et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation (2002) 106:3009-3017.
   PubMed Web of Science ®Google Scholar
• STRAUER BE, BREHM M, ZEUS T et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation (2002) 106:1913-1918.
   PubMed Web of Science ®Google Scholar
• WOLLERT KC, MEYER GP, LOTZ J et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 364:141-148.
   PubMed Web of Science ®Google Scholar
• JANSSENS S, DUBOIS C, BOGAERT J et al.: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 367:113-121.
   PubMed Web of Science ®Google Scholar
• MURRY CE, SOONPA MH, REINECKE H et al.: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature (2004) 428:664-668.
   PubMed Web of Science ®Google Scholar
• LAPIDOS KA, CHEN YE, EARLEY JU et al.: Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftement into cardiac and skeletal muscle. J. Clin. Invest. (2004) 114:1577-1585.
   PubMed Web of Science ®Google Scholar
• MURRY CE, REINECKE H, PABON LM et al.: Regeneration gaps. Observations on stem cells and cardiac repair. JACC (2006) 47:1777-1785.
   Google Scholar